Portage’s Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product Press ReleaseBy Portage Biotech, IncMarch 24, 2015...
Portage’s Biohaven Receives Response from FDA to its Pre-IND Meeting Request Press ReleaseBy Portage Biotech, IncDecember 18, 2014...
Portage Announces Further Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology Press ReleaseBy Portage Biotech, IncDecember 16, 2014...
Portage Completes Non-Brokered Private Placement for Total Proceeds of US$2,000,000 Press ReleaseBy Portage Biotech, IncOctober 16, 2014...
Portage Announces Additional Consultants to Expedite its PPL-003 Development Programs Press ReleaseBy Portage Biotech, IncOctober 6, 2014...
Portage Announces Conversion of Its Debt into Equity Press ReleaseBy Portage Biotech, IncSeptember 29, 2014...
Portage Announces New Consultants for its PPL-003 Development Programs Press ReleaseBy Portage Biotech, IncSeptember 23, 2014...
Portage Announces Proposed Private Placement Press ReleaseBy Portage Biotech, IncSeptember 11, 2014...
Portage’s Biohaven Granted United States Patent for Glutamate Agents in the Treatment of Mental Disorders Press ReleaseBy Portage Biotech, IncAugust 6, 2014...
Portage Announces Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology Press ReleaseBy Portage Biotech, IncJuly 14, 2014...
